Syndax Pharmaceuticals Inc. Common Stock (SNDX)

FairStock Score: 38/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn money, have durable advantages, and sell at a discount to intrinsic value. Syndax is a commercial-stage cancer company with Revuforj and Niktimvo, but it has not earned a profit in any of the last four years; FairStock's computed Lynch category is none for that reason. Revenue is moving in the right direction: in fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $72.8M versus $38.0M in fiscal Q2 2025, while net loss narrowed to $49.4M from $71.8M. For FY2025, revenue was $172.4M and net loss was $285.4M, or EPS -$3.29; FY2024 had revenue of $23.7M and net loss of $318.8M. That is impressive top-line progress, but the business remains deeply unprofitable. Trailing free cash flow is -$220.9M, a -17.7% FCF yield at the 2026-10-13 close of $13.95, and FairStock's Piotroski score is 3/9 with Altman Z at -1.20. At that close, FairStock calculates P/B at 82.06, P/E at -5.56, and ROE at -255.93%. A biotech's moat rests on patents, clinical data, approvals, and reimbursement; these figures do not let me verify a durable moat. Growth is real, but so is cash burn. Without profits or positive cash flow, I cannot call this a Graham bargain or a Buffett-quality compounder. It is a speculative pipeline story on these numbers.

In plain English: Syndax makes cancer medicines. Its sales are growing quickly, but the company still loses money and burns cash. At $13.95, the price looks more like a bet on future drugs than a cheap stock based on today's profits.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer